메뉴 건너뛰기
Drugs in R and D
Volumn 10, Issue 1, 2010, Pages 55-65
Belimumab: Anti-BLyS monoclonal antibody; Benlystatrade; BmAb; LymphoStat-B
[No Author Info available]
Author keywords

arthritis; Autoimmune disorders; Belimumab; Monoclonal antibodies; Research and development; Rheumatoid; Systemic lupus erythematosus; therapeutic se; therapeutic use; treatment
Indexed keywords

BELIMUMAB; BENLYSTA; DISEASE MODIFYING ANTIRHEUMATIC DRUG; PLACEBO; PREDNISONE; UNCLASSIFIED DRUG;
EID: 79953170908     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.2165/11538300-000000000-00000     Document Type: Article
Times cited : (10)
References (39)
  • 5
    • 78649926306 scopus 로고    scopus 로고
    • GlaxoSmithKline Inc, Human Genome Sciences Inc, 20 Apr, Media Release
    • ™ in systemic lupus erythematosus. www.gsk.com, 20 Apr. 2010 Media Release
    • (2010) ™ in Systemic Lupus Erythematosus
  • 6
    • 78649926306 scopus 로고    scopus 로고
    • GlaxoSmithKline, Human Genome Sciences Inc, 20 Apr, Media Release
    • ™ in Systemic Lupus Erythematosus. www.hgsi.com, 20 Apr. 2010 Media Release
    • (2010) ™ in Systemic Lupus Erythematosus
  • 17
    • 44349117767 scopus 로고    scopus 로고
    • Novel combined response endpoint and systemic lupus erythematosus flare index demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy
    • abstr. 1316, No. 9, Sep, USA English
    • Petri M, Furie R, Ginzler E, et al. Novel combined response endpoint and systemic lupus erythematosus flare index demonstrate belimumab (fully human monoclonal antibody to BLyS) improves or stabilizes SLE disease activity and reduces flare rate over 2.5 years of therapy. Arthritis and Rheumatism. 56 (Suppl.): 527 abstr. 1316, No. 9, Sep. 2007. USA [English]
    • (2007) Arthritis and Rheumatism , vol.56 , Issue.SUPPL. , pp. 527
    • Petri, M.1    Furie, R.2    Ginzler, E.3
  • 24
    • 0346026830 scopus 로고    scopus 로고
    • Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphoStat-B (human monoclonal antibody to VLyS) in SLE patients
    • LymphoStat-B Study Group, No. 9, Sep, USA English
    • Furie R, Stohl W, Ginzler E, et al., LymphoStat-B Study Group. Safety, pharmacokinetic and pharmacodynamic results of a phase 1 single and double dose-escalation study of lymphoStat-B (human monoclonal antibody to VLyS) in SLE patients. Arthritis and Rheumatism. 48 (Suppl.): 377, No. 9, Sep. 2003. USA [English]
    • (2003) Arthritis and Rheumatism , vol.48 , Issue.SUPPL. , pp. 377
    • Furie, R.1    Stohl, W.2    Ginzler, E.3
  • 25
    • 77953717315 scopus 로고    scopus 로고
    • Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: Efficacy and safety results from the phase 3 BLISS-52 study
    • abstr. LB1, 16 Oct, Available from URL:, Philippines English
    • Navarra S. Belimumab, a BLyS-Specific Inhibitor, Reduced Disease Activity, Flares and Prednisone use in Patients with Active SLE: Efficacy and Safety Results From the Phase 3 BLISS-52 Study. 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals: abstr. LB1, 16 Oct. 2009. Available from URL: http://www.rheumatology.org. Philippines [English]
    • (2009) 73rd Annual Scientific Meeting of the American College of Rheumatology and the 44th Annual Meeting of the Association of Rheumatology Health Professionals
    • Navarra, S.1
  • 28
    • 79953179120 scopus 로고    scopus 로고
    • Long-term safety profile of belimumab (fully human monoclonal antibody to BLYS) in patients with systemic lupus erythematosus
    • abstr. THU0254, 11 Jun, Available from URL:, USA English
    • Merrill JT, Wallace DJ, McKay J, et al. Long-term safety profile of belimumab (fully human monoclonal antibody to BLYS) in patients with systemic lupus erythematosus. 2008 Annual European Congress of Rheumatology: abstr. THU0254, 11 Jun. 2008. Available from URL: http://www.eular.org. USA [English]
    • (2008) 2008 Annual European Congress of Rheumatology
    • Merrill, J.T.1    Wallace, D.J.2    McKay, J.3
  • 30
    • 24244446279 scopus 로고    scopus 로고
    • Effects of lymphoStat-B, a BLyS antagonist, when administered intravenously to cynomolgus monkeys
    • No. 9, Sep, USA English
    • Halpern WBG, Lappin P, Zanardi T, et al. Effects of lymphoStat-B, a BLyS antagonist, when administered intravenously to cynomolgus monkeys. Arthritis and Rheumatism. 48 (Suppl.): 594, No. 9, Sep. 2003. USA [English]
    • (2003) Arthritis and Rheumatism , vol.48 , Issue.SUPPL. , pp. 594
    • Halpern, W.B.G.1    Lappin, P.2    Zanardi, T.3
  • 31
    • 33646336766 scopus 로고    scopus 로고
    • Belimumab, a novel fully human monoclonal antibody to B-lymphocyte stimulator, selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population
    • plus oral presentation abstr. 1160, No. 9, Sep, USA English. Clinical Trials Insight
    • Stohl W, Chatham W, Weisman M, et al. Belimumab, a novel fully human monoclonal antibody to B-lymphocyte stimulator, selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis and Rheumatism. 52 (Suppl.): 444 (plus oral presentation) abstr. 1160, No. 9, Sep. 2005. USA [English]. Clinical Trials Insight
    • (2005) Arthritis and Rheumatism , vol.52 , Issue.SUPPL. , pp. 444
    • Stohl, W.1    Chatham, W.2    Weisman, M.3
  • 38
    • 79953174069 scopus 로고    scopus 로고
    • Belimumab (fully human monoclonal antibody to BLYS) improved or stabilized systemic lupus erythematosus disease activity and reduced flare rate during 3 years of therapy
    • plus oral presentation abstr. OP-0017, 11 Jun, Available from URL:, USA English
    • Furie R, Petri M, Weisman MH, et al. Belimumab (fully human monoclonal antibody to BLYS) improved or stabilized systemic lupus erythematosus disease activity and reduced flare rate during 3 years of therapy. 2008 Annual European Congress of Rheumatology: (plus oral presentation) abstr. OP-0017, 11 Jun. 2008. Available from URL: http://www.eular.org. USA [English]
    • (2008) 2008 Annual European Congress of Rheumatology
    • Furie, R.1    Petri, M.2    Weisman, M.H.3
  • 39
    • 44349170991 scopus 로고    scopus 로고
    • Progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus patients
    • abstr. 426, No. 9, Sep, USA English
    • Stohl W, Chatham W, McKay J, et al. Progressive normalization of autoantibody, immunoglobulin, and complement levels over 2.5 years of belimumab (fully human monoclonal antibody to BLyS) therapy in systemic lupus erythematosus patients. Arthritis and Rheumatism. 56 (Suppl.): 210 abstr. 426, No. 9, Sep. 2007. USA [English]
    • (2007) Arthritis and Rheumatism , vol.56 , Issue.SUPPL. , pp. 210
    • Stohl, W.1    Chatham, W.2    McKay, J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.